

## Tuesday, September 26

### Bellinzona Institutes of Science building (BIOS+)

14:00-16:00 *Registration and welcome remarks*

#### Opening lectures

16:00-16:40 **Keynote speaker: Davide Robbiani**  
Institute for Research in Biomedicine (IRB), Bellinzona, Switzerland  
*Antibodies against virus and chemokines after COVID-19*

16:40-17:20 **Keynote speaker: Christian Klein**  
Roche, Zürich, Switzerland  
*PD-1 cis-targeting of IL2v with the PD1-IL2v immunocytokine to overcome the limitations of aldesleukin and biased IL-2Rbg agonists*

*Informal, standing dinner (Italian Pizza and drinks) - included with registration fee*

## Wednesday, September 27

### Auditorium Banca Stato

#### Session 1: Immunotherapy of viral diseases

8:30-9:30 *Registration*

9:30-10:00 **Santiago Gonzalez**  
Institute for Research in Biomedicine (IRB), Bellinzona, Switzerland  
*The administration of anti-influenza HA antibodies induces an immunosuppression mechanism that impairs the presentation of antigens by lymph node dendritic cells*

10:00-10:20 Selected abstracts for one oral presentation

10:20-10:40 *Break*

10:40-11:20 **Keynote speaker: Felix Rey**  
Institute Pasteur, Paris, France  
*Virus structure and function*

11:20-11:40 Selected abstracts for one oral presentation

11:40-12:20 **Keynote speaker: Eva Harris**  
University of California (UC), Berkeley, USA  
*Virology, pathogenesis, immunology, and epidemiology of flaviviruses*

12:20-14:00 *Lunch*

## Session 2: Antibody-drug development (Part 1)

- 14:00-14:40      **Keynote speaker: Adriano Aguzzi**  
University of Zürich, Zürich, Switzerland  
***Antibody therapy for prion disease***
- 14:40-15:00      **Selected abstracts for one oral presentation**
- 15:00-15:40      **Keynote speaker: Dario Neri**  
Philogen & ETH Zürich, Siena & Zürich, Italy & Switzerland  
***Antibody-toxin conjugates***
- 15:40-16:00      **Selected abstracts for one oral presentation**
- 16:00-16:20      ***Break***
- 16:20-16:40      **Selected abstracts for one oral presentation**
- 16:40-17:20      **Keynote speaker: Baolin Zhang**  
Food and Drug Administration (FDA), Silver Spring, USA  
***Regulatory aspects in antibody-based therapies***

## **Thursday, September 28**

### **Auditorium Banca Stato**

## Session 3: Immunotherapy of non-viral diseases

- 9:00-9:40      **Keynote speaker: Suzan Rooijackers**  
University Medical Center (UMC), Utrecht, Netherlands  
***Immune response against invading bacteria***
- 9:40-10:20      **Selected abstracts for one oral presentation**
- 10:00-10:20      **Selected abstracts for one oral presentation**
- 10:20-10:40      ***Break***
- 10:40-11:10      **Sarah Gerlo**  
UGent, Gent, Belgium  
***Targeting cytokine activity: towards applications in infectious disease***
- 11:10-11:40      **Fabio Bagnoli**  
GSK, Siena, Italy  
***Immunotherapy against bacterial diseases***
- 11:40-12:00      **Selected abstracts for one oral presentation**

12:00-12:20                    **Selected abstracts for one oral presentation**

12:20-14:00                    ***Lunch***

#### **Session 4: Antibody-drug development (Part 2)**

14:00-14:40                    **Keynote speaker: Giuseppe Pantaleo**  
CHUV, University of Lausanne, Lausanne, Switzerland  
***Pandemic preparedness antibody development***

14:40-15:00                    **Selected abstracts for one oral presentation**

15:00-15:20                    **Selected abstracts for one oral presentation**

15:20-15:50                    **Janice Reichert**  
The antibody society, USA  
***Antibody therapeutics for infectious disease: commercial development trends***

15:50-16:10                    ***Break***

16:10-16:40                    **Arnaud Avril**  
IRBA, Brétigny-sur-Orge, France  
***Development of antibodies for biodefense. The example of an antibody neutralizing several species of Orthopoxvirus***

16:40-17:20                    **Keynote speaker: Davide Corti**  
Humabs BioMed, a subsidiary of VIR Biotechnology, Bellinzona, Switzerland  
***Antibodies against infectious diseases***

## **Friday, September 29**

### **Auditorium Banca Stato**

#### **Session 5: Host-directed immunotherapies**

9:30-10:00                    **Nuria Izquierdo-Useros**  
IrsiCaixa, Badalona, Spain  
***When antigen-presenting cells go viral: targeting viral dissemination with anti-Siglec-1 mAbs***

10:00-10:20                    **Selected abstracts for one oral presentation**

10:20-10:40                    **Selected abstracts for one oral presentation**

10:40-11:00                    ***Break***

11:00-11:30

**Stylianos Bournazos**

The Rockefeller University, NY, USA

***Protective and pathogenic activities of the IgG Fc domain***

Closing lecture

11:30-12:10

**Keynote speaker: Federica Sallusto**

Institute of Research in Biomedicine (IRB) & ETH Zürich, Bellinzona & Zurich,  
Switzerland

***Antibodies against conserved coronavirus epitopes***

12:10-12:30

***Conclusion and remarks***